CLINICAL TRIALS PROFILE FOR AVONEX

All Clinical Trials for AVONEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001785 ↗	Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	1998-09-01	HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body. HTLV-1 has been associated with leukemia and lymphoma. In addition, approximately 1% of all patients infected with HTLV-1 develops a condition known as HTLV-1 associated myelopathy (HAM) / tropical spastic paraparesis (TSP). Currently there is no clearly defined, effective treatment for patients with HAM/TSP. Steroids have been used as therapy but have only been able to provide temporary relief of symptoms. Human interferon is a small protein released from different kinds of cells in the body. Interferon has been known to have antiviral and immunological effects and has been used to treat hepatitis and multiple sclerosis. Interferon Beta is released from cells called fibroblasts. These cells play a role in the production of connective tissue. The purpose of this study is to evaluate the possible role of recombinant interferon beta (Avonex) in treatment of HAM/TSP. The study is broken into three phases, a pre-treatment phase, a treatment phase, and a post-treatment phase. The total duration of the study will be 44 weeks. Patients participating in this study will receive injections of Avonex 1 to 2 times a week. Throughout the study patients will regularly submit blood samples and undergo diagnostic tests such as MRI and measures of somatosensory evoked potentials.
NCT00030966 ↗	Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis	Completed	Elan Pharmaceuticals	Phase 3	2002-01-01	The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
NCT00030966 ↗	Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis	Completed	Biogen	Phase 3	2002-01-01	The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
NCT00037102 ↗	Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis	Completed	Biogen	Phase 4	2001-07-01	The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous methotrexate with Leucovorin rescue.

Clinical Trial Conditions for AVONEX

Condition Name

Condition Name for AVONEX
Intervention	Trials
Multiple Sclerosis	34
Relapsing-Remitting Multiple Sclerosis	14
Multiple Sclerosis, Relapsing-Remitting	8
Relapsing Remitting Multiple Sclerosis	6

Condition MeSH

Condition MeSH for AVONEX
Intervention	Trials
Multiple Sclerosis	65
Sclerosis	59
Multiple Sclerosis, Relapsing-Remitting	34
Multiple Sclerosis, Chronic Progressive	3

Clinical Trial Locations for AVONEX

Trials by Country

Trials by Country for AVONEX
Location	Trials
United States	316
Canada	38
France	38
Poland	35
Germany	34

Trials by US State

Trials by US State for AVONEX
Location	Trials
California	18
North Carolina	17
New York	17
Texas	14
Ohio	14

Clinical Trial Progress for AVONEX

Clinical Trial Phase

Clinical Trial Phase for AVONEX
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	18
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for AVONEX
Clinical Trial Phase	Trials
Completed	52
Terminated	7
Withdrawn	5

Clinical Trial Sponsors for AVONEX

Sponsor Name

Sponsor Name for AVONEX
Sponsor	Trials
Biogen	40
EMD Serono	2
Merck KGaA, Darmstadt, Germany	2

Sponsor Type

Sponsor Type for AVONEX
Sponsor	Trials
Industry	71
Other	30
NIH	5